B
Bruce E. Johnson
Researcher at Harvard University
Publications - 523
Citations - 76494
Bruce E. Johnson is an academic researcher from Harvard University. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 104, co-authored 474 publications receiving 68801 citations. Previous affiliations of Bruce E. Johnson include University of Adelaide & Virginia Tech.
Papers
More filters
Journal ArticleDOI
From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later
James L. Mulshine,Peter Ujhazy,Melissa Antman,Christine M. Burgess,Igor Kuzmin,Paul A. Bunn,Bruce E. Johnson,Jack A. Roth,Harvey I. Pass,Sheila M. Ross,Carolyn R. Aldigé,Ignacio I. Wistuba,John D. Minna +12 more
TL;DR: The intramural the National Cancer Institute and more recently the University of Texas Southwestern Medical Center with many different collaborators comprised a complex, multi‐disciplinary team that collaborated to generated large, comprehensively annotated, cell‐line related research resources which includes associated clinical, and molecular characterization data.
Journal ArticleDOI
Rate of recipient-derived alveolar macrophage development and major histocompatibility complex cross-decoration after lung transplantation in humans
Mark E. Snyder,Anna Bondonese,Andrew Craig,Iulia Popescu,Matthew R. Morrell,Michael M. Myerburg,Carlo J. Iasella,Elizabeth A. Lendermon,Joseph Pilweski,Bruce E. Johnson,S. Kilaru,Yingze Zhang,Humberto E. Trejo Bittar,X. Wang,Pablo G. Sanchez,Fadi G. Lakkis,John F. McDyer +16 more
TL;DR: In this article, the authors characterized the myeloid content of bronchoalveolar lavage and biopsy specimens of lung transplant recipients and found a biphasic rate in AM turnover in the allograft, with a rapid turnover perioperatively, accelerated by both the type of induction immunosuppression and the presence of primary graft dysfunction.
Journal ArticleDOI
O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma
Alan Sandler,Mark G. Kris,Vincent A. Miller,David P. Carbone,William Pao,Dean Billheimer,Anne Tsao,Jyoti D. Patel,Bruce E. Johnson,David W. Johnson +9 more
Journal ArticleDOI
Rates of central nervous system (CNS) metastases in patients with advanced non-small cell lung cancer (NSCLC) and somatic EGFR mutations initially treated with gefitinib or erlotinib versus chemotherapy.
Stephanie Heon,Beow Y. Yeap,Neal I. Lindeman,Michael S. Rabin,David M. Jackman,Bruce E. Johnson +5 more
TL;DR: The data suggest lower rates of CNS progression in EGFR mutant advanced NSCLC patients initially treated with gefitinib or erlotinib compared with upfront chemotherapy.
Journal ArticleDOI
Review: Teriparatide reduces fractures in postmenopausal women with osteoporosis
TL;DR: Source Citation Han SL, Wan SL.